利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.015 秒)

    Anti-Gal3 antibodies and uses thereof
    2.
    发明授权
    Anti-Gal3 antibodies and uses thereof 有权

    公开(公告)号：US11427638B2

    公开(公告)日：2022-08-30

    申请号：US17384542

    申请日：2021-07-23

    申请人： TrueBinding, Inc.

    发明人： Dongxu Sun ,  Yan Wang ,  Yinan Wu ,  Catherine A. Gordon ,  Samuel A. F. Williams

    IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395

    摘要： Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

    ANTI-GAL3 ANTIBODIES AND METHODS OF USE
    6.
    发明申请
    ANTI-GAL3 ANTIBODIES AND METHODS OF USE 有权

    公开(公告)号：US20230036181A1

    公开(公告)日：2023-02-02

    申请号：US17812159

    申请日：2022-07-12

    申请人： TrueBinding, Inc.

    发明人： Dongxu Sun ,  Suhail Rasool ,  Catherine A. Gordon ,  Ke Hong ,  Fan Chen ,  Sara Matilda Bolin ,  Ksenya Shchors ,  Yadong Yu ,  Tsung-Huang Tsai ,  Samuel A.F. Williams ,  Karan Lala ,  Heng Wu ,  Yan Wang

    IPC分类号： C07K16/28 ,  A61P25/28

    摘要： Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

    ANTI-GAL3 ANTIBODIES AND USES THEREOF
    7.
    发明申请
    ANTI-GAL3 ANTIBODIES AND USES THEREOF 有权

    公开(公告)号：US20220002420A1

    公开(公告)日：2022-01-06

    申请号：US17384542

    申请日：2021-07-23

    申请人： TrueBinding, Inc.

    发明人： Dongxu Sun ,  Yan Wang ,  Yinan Wu ,  Catherine A. Gordon ,  Samuel A.F. Williams

    IPC分类号： C07K16/28

    摘要： Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

    ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE
    8.
    发明申请
    ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE 有权

    公开(公告)号：US20220411514A1

    公开(公告)日：2022-12-29

    申请号：US17834703

    申请日：2022-06-07

    申请人： TrueBinding, Inc.

    发明人： Dongxu Sun ,  Ragadeepthi Tunduguru ,  Dalya Rivka Rosner ,  Ksenya Shchors ,  Suhail Rasool

    IPC分类号： C07K16/28 ,  A61P3/10

    摘要： Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or glucose transporters. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, insulin resistance, chronic hyperinsulinemia, dysmetabolic syndrome, type A insulin resistance syndrome, type B insulin resistance syndrome, gestational diabetes, acanthosis nigricans, polycystic ovary syndrome (PCOS), obesity, muscle wasting, cardiovascular diseases, cardiac hypertrophy, myocardial ischemia, hypertension, pancreatic cancer associated diabetes (PCDM), rhabdomyosarcoma, or cancers.

    TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
    10.
    发明公开
    TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND 审中-公开

    公开(公告)号：US20240182564A1

    公开(公告)日：2024-06-06

    申请号：US18354611

    申请日：2023-07-18

    申请人： TRUEBINDING, INC.

    发明人： Dongxu Sun ,  Yan Wang

    IPC分类号： C07K16/28 ,  A61K9/00 ,  A61P35/04 ,  G01N33/574

    CPC分类号： C07K16/2803 ,  A61K9/0019 ,  A61P35/04 ,  G01N33/57492 ,  A61K2039/505

    摘要： Provided herein are methods of activating immune response and/or treating cancer in a patient comprising administering to the patient a Gal3:TIM-3 inhibitor that interferes with the interaction between Gal3 and TIM-3, where said inhibitor is administered in an amount sufficient to activate immune response. Also provided are a humanized anti-Gal3 antibodies that can block the interaction between Gal3 and TIM3 and methods of using the anti-Gal3 antibody to treat cancer. Methods for determining if a patient's cancer is suitable for treatment with a Gal3:TIM-3 inhibitor and methods for selecting compounds that can block interaction between Gal3 and TIM-3, activating immune response and/or treating cancer are also provided.